Press release
Therapeutics Development of Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017: Complete Research and Development History
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1135785
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 44, 51, 1, 3, 53, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 10 and 7 molecules, respectively.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
Table of Contents 2
Introduction 7
Chronic Lymphocytic Leukemia (CLL) - Overview 8
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 9
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 35
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 51
Chronic Lymphocytic Leukemia (CLL) - Drug Profiles 102
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 748
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 756
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 758
Appendix 770
List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2017 29
Number of Products under Development by Companies, H1 2017 31
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 32
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 33
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 34
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 35
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 36
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 37
Number of Products under Development by Universities/Institutes, H1 2017 38
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Therapeutics Development of Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017: Complete Research and Development History here
News-ID: 570271 • Views: …
More Releases for CLL
Expanding Market for Chronic Lymphocytic Leukemia (CLL) Driven by Rising Cancer …
The global chronic lymphocytic leukemia (CLL) market size was USD 10.00 Billion in 2022 and is expected to register a revenue CAGR of 7.8% during the forecast period. A detailed market analysis reveals significant growth in the Chronic Lymphocytic Leukemia (CLL) sector, fueled by a surge in cases of blood cancers, ongoing research advancements, and innovative treatments. This report offers insights into the factors driving revenue, evolving therapeutic options, and…
Chronic Lymphocytic Leukemia (CLL) Treatment Market Expected to Deliver Dynamic …
This Report by Worldwide Market Reports on Chronic Lymphocytic Leukemia (CLL) Treatment Market 2023 is a detailed analysis of the market providing you with the latest industry data and future market trends. The details and data in the report will allow you to identify three important factors in the market which are products, revenue, and growth profitability. The Chronic Lymphocytic Leukemia (CLL) Treatment market offers company profiling, product specifications, sales,…
Pruritus Drugs Market Exclusive insight on Transformation 2028 | Granulomatosis …
Global Pruritus Drugs Market: Overview
Transdermal drug delivery system is the most preferred way to inject pruritus drugs. Most of the pruritus drugs that are available in the market are in the semi-solid topical dosage state. It includes forms such as creams, gels, and lotions. These products are quite easy to apply, give no or less pain, and are quicker in terms of delivering desired effect as compared to other drug…
Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices Market 2017 F. Ho …
Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices Market Research Report
A market study based on the " Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices Market 2017’. The research report analyses the historical as well as present performance of the worldwide Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices industry, and makes predictions…
Global CLL Therapeutics Market To Grow At A CAGR Of 19.16% During The Period 201 …
Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports.
Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia…
Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Chronic Lymphocytic Leuke …
The global chronic lymphocytic leukemia therapeutics market is expected to create more opportunities in oncology due to promising pipeline and positive clinical data of drug candidates. The existing drugs for the treatment of chronic lymphocytic leukemia is the be most effective treatment. The American Cancer Society, and other regulatory bodies are supporting the chronic lymphocytic leukemia therapeutics market by providing funding and grants. The market is being driven by different…
